Submit Deal

Announced

5 Aug 2021

Completed

5 Aug 2021

Insmed completed the acquisition of Motus Biosciences for $288m.

Synopsis

Insmed, a global biopharmaceutical company, completed the acquisition of Motus Biosciences, a developer of tools intended for the development of next-generation gene therapies, for $288m.

Principals

target

Motus Biosciences

bidder

Insmed

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Bidder Team (12)

sara m. bonstein

CFO at INSMED INC

Manager

bidder

Deal

£ 201 M

Total Value

william h. lewis

CEO at INSMED INC

Manager

bidder

Deals

£ 201 M

Total Value

geoffrey allan

Chairman at INSMED INC

Manager

bidder

Deal

£ 201 M

Total Value

benjamin weksberg

Associate at Covington & Burling

Lawyer

bidder

Deals

£ 598 M

Total Value

jon endean

Associate at Covington & Burling

Lawyer

bidder

Deals

£ 29.27 B

Total Value

stephanie l. resnik

Associate at Covington & Burling

Lawyer

bidder

Deals

£ 765 M

Total Value

christen sewell

Special Counsel at Covington & Burling

Lawyer

bidder

Deals

£ 2.59 B

Total Value

lauren visek

Associate at Covington & Burling

Lawyer

bidder

Deals

£ 1.93 B

Total Value

ansgar simon

Partner at Covington & Burling

Lawyer

bidder

Deals

£ 38.12 B

Total Value

erica wu

Associate at Covington & Burling

Lawyer

bidder

Deals

£ 884 M

Total Value

beth braiterman

Associate at Covington & Burling

Lawyer

bidder

Deal

£ 201 M

Total Value

michael k. stern

Of Counsel at Covington & Burling

Lawyer

bidder

Deals

£ 16.65 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy